The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the ...

The first mpox vaccine approved by the WHO is MVA-BN, made by Bavarian Nordic A/S. It was approved for emergency use and can be used "off-label" in infants, children and adolescents as well as in ...

Bavarian Nordic said on Thursday its mpox vaccine was approved by the EU's drug regulator for use in adolescents, bolstering the case for using the shot in the 12 to 17 age group to contain an ...

The World Health Organization says it has cleared Bavarian Nordic's mpox vaccine, the first such vaccine to be approved by the agency for containing the spread of the disease in badly hit African ...

Key takeaways: Jynneos was safe and generated an antibody response in adolescents that was similar to that seen in adults. The new data could help expand the number of people eligible for the vaccine.

Bavarian Nordic’s Mpox vaccine met with the World Health Organization's approval on Monday for use among adolescents aged between 12-17. This age bracket is considered to be highly vulnerable to ...